All In Biotech

Drug Trial Radar · NCT03757234

IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis

A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of iv or iv/po Omadacycline and iv/po Levofloxacin in the Treatment of Adults With Acute Pyelonephritis.

Last checked: Nov 20, 2026Latest source record: Jul 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 201 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

201

Actual

Start

Nov 19, 2018

Primary completion

Jun 26, 2019

Study completion Jul 24, 2019

Sponsor

Lead sponsor
Paratek Pharmaceuticals IncIndustry
Sponsor type
Industry
First posted
Nov 28, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the safety and efficacy of intravenous (iv) or iv/per oral (po) omadacycline as compared to iv or iv/po levofloxacin in the treatment of female adults with acute pyelonephritis.

Conditions

  • Acute Pyelonephritis

Interventions

  • OmadacyclineDrug

    po tablets

  • LevofloxacinDrug

    iv solution/po tablets

  • OmadacyclineDrug

    iv solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With an Investigator Assessment of Clinical Response at the Post Therapy Evaluation (PTE) Visit (ITT Population)Time frame: Day 21 (A PTE occurred on Day 21 ± 2 days after the participant's first dose of study drug).
  2. Number of Participants With a Microbiological Response at the PTE Visit (Micro-ITT Population)Time frame: Day 21 (A PTE occurred on Day 21 ± 2 days after the participant's first dose of study drug).
  3. Number of Participants With Resolution of All AP Signs and Clinical Symptoms at PTE Visit (ITT Population)Time frame: Day 21 (A PTE occurred on Day 21 ± 2 days after the participant's first dose of study drug).
  4. Number of Participants With No Worsening and Absence of New AP Signs and Clinical Symptoms at PTE Visit (ITT Population)Time frame: Day 21 (A PTE occurred on Day 21 ± 2 days after the participant's first dose of study drug).

Locations

31 sites in 4 countries. Site status is shown where the registry gives one.

  • Site 201

    Tbilisi, Georgia

  • Site 202

    Tbilisi, Georgia

  • Site 203

    Tbilisi, Georgia

  • Site 204

    Tbilisi, Georgia

  • Site 301

    Daugavpils, Latvia

  • Site 304

    Liepāja, Latvia

  • Site 305

    Rēzekne, Latvia

  • Site 302

    Riga, Latvia

  • Site 303

    Valmiera, Latvia

  • Site 409

    Krasnoyarsk, Russia

  • Site 408

    Moscow, Russia

  • Site 410

    Moscow, Russia

  • Site 415

    Penza, Russia

  • Site 407

    Rostov-on-Don, Russia

  • Site 405

    Rostov-on-Don, Russia

  • Site 411

    Saint Petersburg, Russia

  • Site 406

    Saint Petersburg, Russia

  • Site 402

    Saint Petersburg, Russia

  • Site 412

    Saint Petersburg, Russia

  • Site 403

    Saint Petersburg, Russia

  • Site 414

    Saint Petersburg, Russia

  • Site 401

    Saint Petersburg, Russia

  • Site 404

    Saint Petersburg, Russia

  • Site 413

    Smolensk, Russia

  • Site 502

    Chernivtsi, Ukraine

  • Site 506

    Dnipro, Ukraine

  • Site 505

    Kharkiv, Ukraine

  • Site 504

    Kyiv, Ukraine

  • Site 503

    Kyiv, Ukraine

  • Site 501

    Lviv, Ukraine

  • Site 507

    Zaporizhzhya, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.